Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University have reported on the design of an ultra-high affinity ACE2 variant that has been coupled to an Fc domain incorporating mAbsolve’s STR mutations for silencing and the YTE mutations for half-life extension. It is hoped that this molecule can be developed as a variant agnostic and cost effective prophylactic that might be able to be administered nasally.

Posted in